Petr Arenberger

Nivolumab for Resected Stage III or IV Melanoma at 9 Years.

Gerandomiseerde, Open-Label, Fase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in...

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Behandeling - Update 2024.

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma...

T-VEC plus pembrolizumab versus pembrolizumab bij melanoom: MASTERKEY-265 fase III definitief

Adjuvant nivolumab versus ipilimumab bij melanoom: CheckMate 238 vierjaars herbeoordeling

Melanoomdiagnostiek: Europese consensus 2022 update deel 1

Melanoombehandeling: Europese consensus 2022 update deel 2

Adjuvant nivolumab versus ipilimumab bij melanoom: CheckMate 238 vierjaars